Everything I've ever read has said prop is a half life of 4 days, although I have seen some pieces of literature saying as low as 1.5 days. Most of the forums will say 4 days, although the only real sources I've seen are pretty old, it's impossible to yell what's reliable...
Most forums are unreliable and are only about self product promotion...
Testosterone propionate 2 days
Testosterone phenylpropionate 2 days
Nandrolone phenylpropionate 2 days
Isocaproato testosterone 4 days
Testosterone decanoate 7days
Nandrolone decanoate 6-7 days
Testosterone cypionate 6 days
Testosterone enanthate 5 days
Propionic drostanolone 2 days
Methenolone Enanthate 5 days
Boldenone undecylenate 7 days
Trenbolone Acetate 1.5 days
Trenbolone Enanthate 5-6 days
Oral - 17aa (Time in hours approximately)
Stanozolol 7-9 hours
Oxandrolone 4-6 hours
Methandrostenolone 4-6 hours
Oxymetholone 5-6 hours
Why these values are so low in relation to the previous tables?
Simply because the previous tables were based on the theory of a famous writer on steroids Bill Roberts, who made them years ago to show that the half-life of a steroid was just multiply the amount of ester carbons by 1.5, ie the Testosterone Propionate has three carbons in the ester would then have 4.5 days of half-life... testosterone decanoate would have 15 days. Unfortunately, your metabolism does not know mathematica, this formula seems simple, but does not work in practice. So the table is totally outdated as today it has studies "in vivo" for almost all drugs on the market, with values much more reliable than those proposed in the theory of Bill Roberts.
References: Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy Volunteers - HP Wijnand, AM Bosch, CW Donker; Hormone kinetics after intramuscular testosterone cypionate - Nankin HR.
Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate Assessed by the serum and salivary testosterone levels in normal men - Schurmeyer T, Nieschlag E,
A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men J Androl 1998 Nov-Dec; 19 (6): 761 - 8; Beerbuhl Schulte M et al.
Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertility and Sterility (1980) 33.2: 201-203;
United States Pharmacopeial Convention, USP DI: Drug Information for the Health Care Professional, 1993, 108. Rand McNally, Taunton Mass.
Weinbauer, GF, Jackwerth B, et al. Acta Endocrinol. Copenhagen or Lisbon., 1990, 122, 432-42 Belkien, L.; Schurmeyer, T., et al.
J. Steroid Biochem; etabolism of Anabolic Androgenic Steroids. V. Rogozkin. 1991 CRC press
Metabolism of synthetic steroids. Fotherby K, James F. Adv Steroid Biochem Pharmacol 1972 3: 67-165;
Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate to healthy Volunteers. Wijnand, Bosch and Donker. Acta Endocrinol 1985 (suppl 271) 19-30; Implications of basic pharmacology in the therapy with esters of nandrolone. Acta Endocrinol 1985 (suppl 271) 38-43
1. Anderson RA, Wu FC (1996) Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab 81: 896–901 CrossRef
2. Anderson RA, Wallace AM, Kicman AT, Wu FC (1997) Comparison between testosterone en-anthate-induced azoospermia and oligozoospermia in a male contraceptive study. IV. Suppression of endogenous testicular and adrenal androgens. Hum Reprod 128: 1657–1662 CrossRef
3. Behre HM, Nieschlag E (1992): Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75: 1204–1210 CrossRef
4. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80: 2394–2403 CrossRef
5. Cantrill AJ, Dewis P, Large DM, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol 21: 97–107CrossRef
6. Collier PS (1989) Mean residence time: some further considerations. Biopharm Drug Dispos 10: 443–451 CrossRef
7. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11: 247–264 CrossRef
8. Cunningham GR, Silverman VE, Kohler PO (1978) Clinical evaluation of testosterone en-anthate for induction and maintenance of reversible azoospermia in man. In: Patanelli DJ (ed) Hormonal control of male fertility. Department of Health, Education and Welfare. National Institutes of Health, Bethesda, Md, Publ No (NIH) 78–1097, pp 71–87
9. Cutler DJ (1987) Definition of mean residence times in pharmacokinetics. Biopharm Drug Dispos 8: 87–97 CrossRef
10. Demisch K, Nickelsen T (1983) Distribution of testosterone in plasma proteins during replacement therapy with testosterone enanthate in patients suffering from hypogonadism. Andrologia 15: 536–541 CrossRef
11. Fujioka M, Shinohara Y, Baba S, Irie M, Inoue K (1986) Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 63: 1361–1364 CrossRef
12. Fukutani K, Isurugi K, Takayasu H, Wakabayashi K, Tamaoki B-I (1974) Effects of depot testosterone therapy on serum levels of luteinizing hormone and follicle-stimulating hormone in patients with Klinefelters syndrome and hypogonadotropic eunuchoidism. J Clin Endocrinol Metab 39: 856–864 CrossRef
13. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, In., New York Gladtke E, von Hattingberg HM (1977) Pharmakokinetik. 2nd ed Springer, Berlin, Heidelberg, New York
14. Junkmann K (1952) Über protrahiert wirksame Androgene. Arch Path Pharmacol 215:85–92 Junkmann K (1957) Long-acting steroids in reproduction. Recent Prog Horm Res 13: 389–419
15. Maisey NM, Bingham J, Marks V, English J, Chakraborty J (1981) Clinical efficacy of testosterone undecanoate in male hypogonadism. Clin Endocrinol 14: 625–629 CrossRef
16. Mayer PR, Brazzell RK (1988) Application of statistical moment theory to pharmacokinetics. J Clin Pharmacol 28: 481–483
17. Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ (1997). Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther 281: 93–102.
18. Nankin HR (1987) Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 47: 1004–1009
19. Nieschlag E, Behre HM (1997) Male contribution to contraception - experimental approaches. In: Nieschlag E, Behre HM (eds) Andrology - Male reproductive health and dysfunction. Berlin, Heidelberg, New York: Springer-Verlag, pp 386–393
20. Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ (1976) Bioavailability and LH-sup- pressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7: 138–145 CrossRef